<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45228">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912326</url>
  </required_header>
  <id_info>
    <org_study_id>B01- 408</org_study_id>
    <nct_id>NCT01912326</nct_id>
  </id_info>
  <brief_title>Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation</brief_title>
  <acronym>PAFOS</acronym>
  <official_title>Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of dynamic Atrial Overdrive Stimulation using the AF Suppression Algorithm to
      prevent atrial tachyarrhythmias in patients with more than 2% Auto Mode Switch Episodes with
      optimized pacemaker programming.

      Hypothesis:

      Dynamic atrial Overdrive (AF Suppression) reduces AT/AF Burden by 30% as compared to
      programming DDDR-(60) without AF Suppression when all other parameters are optimized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial Fibrillation is the most common Heart Rhythm Disorder requiring therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Reduction of AT/AF Burden in the pacemaker diagnostics</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Bradycardia</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AF Suppression On</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AF Suppression Algorithm On, optimized AF Pacemaker Programming</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AF Suppression Off</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AF Suppression programmed Off, Optimized Pacemaker Programming</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker Implantation</intervention_name>
    <description>Implantation of a dual chamber pacemaker</description>
    <arm_group_label>AF Suppression On</arm_group_label>
    <arm_group_label>AF Suppression Off</arm_group_label>
    <other_name>Pacemaker St. Jude Medical Identity DR Model 5370 or 5376</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indication for dual chamber pacemaker

          -  documented paroxysmal or persistent Atrial Fibrillation

          -  P-wave &gt;1.0 mV in Sinus Rhythm or sufficient detection of AFib

          -  stable antyarrhythmic therapy

          -  age &gt;= 19 years

          -  written informed consent

          -  implantation of a Identity DR 5370/5376 or later

          -  bipolar atrial lead

        Exclusion Criteria:

          -  permanent AFib

          -  reversible etiology of AFib

          -  HYHA II or IV

          -  Coronary Artery disease with stable angina pectoris

          -  implanted ICD or planned implantation of a ICD

          -  cardiac surgery within the last 6 months or planned within 12 months

          -  live expectancy &lt; 12 months

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 26, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pacemaker</keyword>
  <keyword>atrial fibrillation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
